CNP 520

Drug Profile

CNP 520

Alternative Names: AMG 520; CNP520

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Amgen; Novartis
  • Class Antidementias; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease

Most Recent Events

  • 03 Aug 2017 Phase-II/III clinical trials in Alzheimer's disease in Puerto Rico, Spain (PO) (NCT03131453) (EudraCT2016-002976-28)
  • 03 Aug 2017 Novartis initiates enrolment in the Generation S2 phase-II/III trial for Alzheimer's disease in USA (PO) (NCT03131453) (EudraCT2016-002976-28)
  • 16 Jul 2017 Safety, tolerability, pharmacokinetic and pharmacodynamic data from a phase IIa trial in Alzheimer’s disease presented at the Alzheimer’s Association International Conference 2017 (AAIC 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top